ANDA 78278, held by Cipla. Famciclovir.
As of Nov 16, 2026, ANDA 78278 (Famciclovir), held by Cipla, was first approved by FDA on Mar 21, 2011, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 21, 2011 | Original application | Approved | None posted |
| Famciclovir125MG · tablet;oral | Famciclovir | Discontinued |
| Famciclovir250MG · tablet;oral | Famciclovir | Discontinued |
| Famciclovir500MG · tablet;oral | Famciclovir | Discontinued |
| Jul 8, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 8, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 30, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 13, 2011 | Supplement 2Labeling | Approved | None posted |
| Mar 21, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters